{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:54:37Z","timestamp":1790848477229,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":275,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Olanzapine is an inexpensive and durable agent for the treatment of chemotherapy-induced nausea and vomiting and is also superior to neurokinin-1 receptor antagonists in the control of nausea. This study aimed to investigate the efficacy and safety of a low dose of 5 mg olanzapine plus granisetron and dexamethasone for treatment of carboplatin (CBDCA)-induced nausea and vomiting in patients with thoracic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We conducted a prospective, open-label, single-arm, multicenter, phase II trial in four centers in Japan. Registered patients were scheduled to receive area under the curve (AUC) \u22655 mg\/mL per minute of CBDCA and had never received moderately to highly emetogenic chemotherapy. Patients received olanzapine 5 mg\/day orally after supper for 4\u2009days, in combination with granisetron and dexamethasone. Primary endpoint was complete response (CR; no emesis and no use of rescue medication) rate during the overall phase (0\u2013120 hours).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between February 2018 and June 2020, 51 patients were enrolled, and 50 patients were evaluated. The CR rates in the overall (0\u2013120 hours), acute (0\u201324 hours), and delayed phases (24\u2013120 hours) were 94.0%, 100%, and 94.0%, respectively. No grade 3 or higher adverse effects of olanzapine were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prophylactic antiemetic therapy with a low dose of 5 mg olanzapine plus granisetron and dexamethasone showed durable efficacy with an acceptable safety profile. This three-drug combination appears to be a reasonable treatment approach in patients with thoracic malignancies receiving an AUC \u22655 mg\/mL per minute of CBDCA-based regimen. Clinical trial identification number: UMIN000031267.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>The results of this phase II trial indicated that the prophylactic administration of low-dose of 5 mg olanzapine combined with granisetron and dexamethasone has promising activity with acceptable safety profile in patients with thoracic malignancy receiving high-dose carboplatin chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/onco.13772","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T15:30:12Z","timestamp":1617463812000},"page":"e1066-e1072","source":"Crossref","is-referenced-by-count":17,"title":["Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial"],"prefix":"10.1093","volume":"26","author":[{"given":"Chizuru","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan"},{"name":"Cancer Biostatistics Laboratory, Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Minami-ku, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-454X","authenticated-orcid":false,"given":"Hirotoshi","family":"Iihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu, Gifu, Japan"},{"name":"Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnosuke","family":"Ikemura","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan"},{"name":"Keio Cancer Center, Keio University, School of Medicine, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Hirose","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mie","family":"Kotake","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Funaguchi","sequence":"additional","affiliation":[{"name":"Department of Respirology, Asahi University Hospital, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenobu","family":"Gomyo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan"},{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan (present address)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hakamata","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Keio University Hospital, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daizo","family":"Kaito","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Gunma Prefectural Cancer Center, Ohta, Gunma, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kawazoe","sequence":"additional","affiliation":[{"name":"Division of Pharmaceutical Care Sciences, Center for Social Pharmacy and Pharmaceutical Care Sciences, Keio University Faculty of Pharmacy, Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gifu University Hospital, Gifu, Gifu, Japan"},{"name":"Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ohno","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Okura","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Respiratory Medicine, Gifu University Graduate School of Medicine, Gifu, Gifu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"2022020821443249700_onco13772-bib-0001","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"2022020821443249700_onco13772-bib-0002","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdt178","article-title":"Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Fr\u00fch","year":"2013","journal-title":"Ann Oncol"},{"key":"2022020821443249700_onco13772-bib-0003","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1200\/JCO.2015.63.7918","article-title":"Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline","volume":"33","author":"Rudin","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022020821443249700_onco13772-bib-0004","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.03022","article-title":"Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"38","author":"Hanna","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020821443249700_onco13772-bib-0005","volume-title":"Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 8.2020","author":"NCCN"},{"key":"2022020821443249700_onco13772-bib-0006","volume-title":"Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 1.20211","author":"NCCN"},{"key":"2022020821443249700_onco13772-bib-0007","volume-title":"Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1. 2020","author":"NCCN"},{"key":"2022020821443249700_onco13772-bib-0008","volume-title":"Clinical Practice Guidelines in Oncology: Malignant Pleural Mesothelioma. Version 1.2020","author":"NCCN"},{"key":"2022020821443249700_onco13772-bib-0009","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"2022020821443249700_onco13772-bib-0010","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2022020821443249700_onco13772-bib-0011","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"key":"2022020821443249700_onco13772-bib-0012","volume-title":"Clinical Practice Guidelines in Oncology: Antiemesis. Version 2.2020","author":"NCCN"},{"key":"2022020821443249700_onco13772-bib-0013","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: Analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support Care Cancer"},{"key":"2022020821443249700_onco13772-bib-0014","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support Care Cancer"},{"key":"2022020821443249700_onco13772-bib-0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00520-010-1073-9","article-title":"Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study","volume":"20","author":"Hilarius","year":"2012","journal-title":"Support Care Cancer"},{"key":"2022020821443249700_onco13772-bib-0016","first-page":"711","article-title":"Kubota K et al","volume":"104","author":"Sekine","year":"2013","journal-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis Cancer Sci"},{"key":"2022020821443249700_onco13772-bib-0017","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomized, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70\u2009years receiving moderately emetogenic chemotherapy","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br J Cancer"},{"key":"2022020821443249700_onco13772-bib-0018","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","article-title":"Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"2022020821443249700_onco13772-bib-0019","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2014.03.017","article-title":"Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy","volume":"84","author":"Ito","year":"2014","journal-title":"Lung Cancer"},{"key":"2022020821443249700_onco13772-bib-0020","first-page":"3939","article-title":"A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancy","volume":"32","author":"Endo","year":"2012","journal-title":"Anticancer Res"},{"key":"2022020821443249700_onco13772-bib-0021","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","article-title":"Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer","volume":"90","author":"Kusagaya","year":"2015","journal-title":"Lung Cancer"},{"key":"2022020821443249700_onco13772-bib-0022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00520-014-2339-4","article-title":"Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients receiving cisplatin-based or carboplatin-based chemotherapy","volume":"23","author":"Kitazaki","year":"2015","journal-title":"Support Care Cancer"},{"key":"2022020821443249700_onco13772-bib-0023","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1186\/s40064-016-3769-x","article-title":"Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, and aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy","volume":"5","author":"Miya","year":"2016","journal-title":"Springerplus"},{"key":"2022020821443249700_onco13772-bib-0024","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J Support Oncol"},{"key":"2022020821443249700_onco13772-bib-0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"2022020821443249700_onco13772-bib-0026","article-title":"The efficacy, safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: A pilot study from South India","volume":"2016","author":"Babu","year":"2016","journal-title":"Chemother Res Pract"},{"key":"2022020821443249700_onco13772-bib-0027","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12013-014-0489-0","article-title":"Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer","volume":"72","author":"Wang","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"2022020821443249700_onco13772-bib-0028","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"2022020821443249700_onco13772-bib-0029","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1634\/theoncologist.2017-0378","article-title":"Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: A network meta-analysis","volume":"23","author":"Zhang","year":"2018","journal-title":"The Oncologist"},{"key":"2022020821443249700_onco13772-bib-0030","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","article-title":"A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study","volume":"15","author":"Navari","year":"2007","journal-title":"Support Care Cancer"},{"key":"2022020821443249700_onco13772-bib-0031","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s10147-017-1200-4","article-title":"A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy","volume":"23","author":"Yanai","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"2022020821443249700_onco13772-bib-0032","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bcp.13322","article-title":"Aprepitant and fosaprepitant drug interactions: A systematic review","volume":"83","author":"Patel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2022020821443249700_onco13772-bib-0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00520-017-3857-7","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?- Systematic review and meta-analysis","volume":"26","author":"Jordan","year":"2018","journal-title":"Support Care Cancer"},{"key":"2022020821443249700_onco13772-bib-0034","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1634\/theoncologist.2019-0292","article-title":"A nationwide, multicenter registry study of antiemesis for carboplatin-based chemotherapy-induced nausea and vomiting in Japan","volume":"25","author":"Iihara","year":"2020","journal-title":"The Oncologist"},{"key":"2022020821443249700_onco13772-bib-0035","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-019-03868-5","article-title":"Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting","volume":"84","author":"Tanaka","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022020821443249700_onco13772-bib-0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","article-title":"Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron, and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study","volume":"156","author":"Iihara","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2022020821443249700_onco13772-bib-0037","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12885-021-07802-y","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: A propensity score-matched analysis","volume":"21","author":"Hayashi","year":"2021","journal-title":"BMC Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e1066\/42375577\/oncolo_26_6_e1066.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/6\/e1066\/42375577\/oncolo_26_6_e1066.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:52:54Z","timestamp":1644339174000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/6\/e1066\/6520945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,5,4]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13772","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,1]]},"published":{"date-parts":[[2021,5,4]]}}}